Pneumococcal Vaccines in Patients With Asthma

Overview

About this study

Investigators are assessing if patients with asthma respond better to the Pneumovax vaccine if they are given Prevnar initially.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Diagnosis of asthma

Exclusion Criteria:

Research exemption requested
History of PCV-13 vaccination
History of cochlear implant
Cerebrospinal Fluid (CSF) leak
Congestive Heart Failure (CHF)
Diabetes Mellitus (DM)
Chronic Kidney Disease (CKD)
Human Immunodeficiency Virus (HIV)
Common Variable Immune Deficiency (CVID)
Patients who have received the PPSV23 vaccine in the last 5 years
Women who are pregnant will also be excluded from the study by performing 2 point of care urine pregnancy tests ( prior to vaccinations)

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Avni Joshi, M.D., M.S.	Closed for enrollment	Contact information: Alexandra Graden M.D. Graden.Alexandra@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Avni Joshi, M.D., M.S.

Closed for enrollment

Contact information:

Alexandra Graden M.D.

Graden.Alexandra@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials